Latest Period
Q1 2026
Security Snapshot
MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX) Institutional Ownership
CUSIP: 61559X104
13F Institutional Holders and Ownership History from Q1 2022 to Q1 2026
Institutions Reporting
146
Shares (Excl. Options)
63,048,574
Price
$18.64
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A ordinary share, par value $0.0001 per share
- Symbol
- MLTX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 63,048,574
- Total 13F value
- $1,173,295,788
- Portfolio coverage rank
- 0%
- Share change
- +6,588,977
- Value change
- +$130,741,418
- Number of holders
- 146
- Shares outstanding
- 71,686,928
- SEC-reported price per share
- $18.68
- Insider filing price
- $18.68
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- MLTX - MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share is tracked under CUSIP 61559X104.
- 146 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 130 to 146 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $742,946,894 to $1,173,295,788.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 146 institutions filings for Q1 2026.
Security key
61559X104
Latest holder period
Q1 2026
13F holders
146
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
MLTX full holder history
MoonLake Immunotherapeutics SEC filings
MoonLake Immunotherapeutics company facts
MoonLake Immunotherapeutics insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 61559X104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
MLTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 22% | -19% | $283,062,714 | -$66,337,500 | 16,001,284 | -19% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| Deep Track Capital, LP | 6.5% | $33,054,209 | 4,610,071 | Deep Track Capital, LP | 05 Nov 2025 | |||
| Cormorant Asset Management, LP | 6.2% | +2.5% | $83,515,271 | +$2,330,000 | 4,480,433 | +2.9% | Cormorant Asset Management, LP | 31 Mar 2026 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.7% | -12% | $117,334,991 | -$14,571,725 | 2,974,271 | -11% | T. Rowe Price Associates, Inc. | 31 Mar 2025 |
| Avoro Capital Advisors LLC | 3.2% | -48% | $14,340,000 | -$15,415,500 | 2,000,000 | -52% | Avoro Capital Advisors LLC | 30 Sep 2025 |
| Chen Bihua | 3.1% | $108,084,177 | 1,994,173 | Chen Bihua | 30 Sep 2025 | |||
| FMR LLC | 1.1% | -88% | $5,212,098 | -$35,678,759 | 726,931 | -87% | FMR LLC | 30 Sep 2025 |
As of 31 Mar 2026, 146 institutional investors reported holding 63,048,574 shares of MoonLake Immunotherapeutics - Class A ordinary share, par value $0.0001 per share (MLTX). This represents 88% of the company’s total 71,686,928 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BVF INC/IL | 22% | 16,001,284 | -19% | 9.5% | $298,263,934 |
| Deep Track Capital, LP | 8.9% | 6,408,863 | +39% | 2.5% | $119,461,206 |
| Cormorant Asset Management, LP | 6.2% | 4,480,433 | +2.9% | 4.2% | $83,515,271 |
| JANUS HENDERSON GROUP PLC | 4.8% | 3,451,628 | +65% | 0.03% | $64,303,830 |
| D. E. Shaw & Co., Inc. | 3.3% | 2,390,661 | -3.6% | 0.04% | $44,561,921 |
| MPM BIOIMPACT LLC | 2.5% | 1,811,082 | 2.6% | $33,758,568 | |
| Weiss Asset Management LP | 2.4% | 1,708,328 | +413% | 0.59% | $31,843,234 |
| Logos Global Management LP | 2.1% | 1,500,000 | -14% | 1.4% | $27,960,000 |
| Point72 Asset Management, L.P. | 1.9% | 1,368,518 | +77% | 0.04% | $25,509,176 |
| CITADEL ADVISORS LLC | 1.8% | 1,323,728 | +248% | 0.02% | $24,674,290 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.8% | 1,294,861 | +35% | 0% | $24,137,000 |
| GOLDMAN SACHS GROUP INC | 1.6% | 1,130,233 | +318% | 0% | $21,067,543 |
| TWO SIGMA INVESTMENTS, LP | 1.6% | 1,122,312 | +43% | 0.02% | $20,919,896 |
| JPMORGAN CHASE & CO | 1.5% | 1,088,514 | +30% | 0% | $18,428,542 |
| Balyasny Asset Management L.P. | 1.5% | 1,065,610 | -32% | 0.04% | $19,862,970 |
| BlackRock, Inc. | 1.4% | 1,021,851 | +257% | 0% | $19,047,302 |
| Vivo Capital, LLC | 1.4% | 1,000,000 | 0% | 1.5% | $18,640,000 |
| Candriam S.C.A. | 1.1% | 818,126 | +509% | 0.08% | $15,249,869 |
| BANK OF AMERICA CORP /DE/ | 1% | 724,794 | +5256% | 0% | $13,510,160 |
| MORGAN STANLEY | 0.86% | 614,482 | -41% | 0% | $11,453,948 |
| Holocene Advisors, LP | 0.84% | 600,000 | 0.03% | $11,184,000 | |
| MILLENNIUM MANAGEMENT LLC | 0.8% | 576,092 | -28% | 0.01% | $10,738,355 |
| Jefferies Financial Group Inc. | 0.7% | 500,000 | 0% | 0.11% | $9,320,000 |
| GREAT POINT PARTNERS LLC | 0.7% | 500,000 | 2.3% | $9,320,000 | |
| Trexquant Investment LP | 0.69% | 495,336 | +169% | 0.07% | $9,233,063 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
17
Latest
Q1 2026
Rows shown
1-17 of 17
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 63,048,574 | $1,173,295,788 | +$130,741,418 | $18.64 | 146 |
| 2025 Q4 | 56,366,068 | $742,946,894 | +$285,748,230 | $13.18 | 130 |
| 2025 Q3 | 37,454,837 | $268,355,896 | -$543,765,841 | $7.17 | 132 |
| 2025 Q2 | 58,588,386 | $2,765,378,029 | -$36,637,296 | $47.20 | 129 |
| 2025 Q1 | 59,723,013 | $2,333,397,891 | -$153,122,113 | $39.07 | 134 |
| 2024 Q4 | 63,244,825 | $3,424,722,298 | +$68,390,992 | $54.15 | 114 |
| 2024 Q3 | 62,105,859 | $3,131,140,770 | +$81,133,174 | $50.42 | 108 |
| 2024 Q2 | 60,656,094 | $2,667,012,692 | +$45,095,266 | $43.97 | 109 |
| 2024 Q1 | 59,346,206 | $2,980,958,004 | +$1,466,170 | $50.23 | 112 |
| 2023 Q4 | 58,433,271 | $3,528,831,635 | +$147,969,282 | $60.39 | 124 |
| 2023 Q3 | 56,323,727 | $3,210,450,399 | +$46,563,145 | $57.00 | 118 |
| 2023 Q2 | 56,057,516 | $2,858,934,462 | +$861,230,424 | $51.00 | 82 |
| 2023 Q1 | 39,419,149 | $843,176,754 | +$59,244,738 | $21.39 | 43 |
| 2022 Q4 | 37,748,780 | $396,358,589 | +$8,234,061 | $10.50 | 32 |
| 2022 Q3 | 36,855,847 | $291,356,995 | +$3,123,162 | $7.76 | 24 |
| 2022 Q2 | 36,470,008 | $190,106,000 | +$182,848,000 | $5.25 | 22 |
| 2022 Q1 | 653,872 | $7,258,000 | +$7,258,000 | $11.10 | 1 |